Shanghai Kaibao Pharmaceutical (300039) - Total Assets
Based on the latest financial reports, Shanghai Kaibao Pharmaceutical (300039) holds total assets worth CN¥4.96 Billion CNY (≈ $725.53 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check 300039 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Shanghai Kaibao Pharmaceutical - Total Assets Trend (2006–2024)
This chart illustrates how Shanghai Kaibao Pharmaceutical's total assets have evolved over time, based on quarterly financial data. Explore 300039 long-term investment intensity to see how much of total assets are deployed in long-term investments.
Shanghai Kaibao Pharmaceutical - Asset Composition Analysis
Current Asset Composition (December 2024)
Shanghai Kaibao Pharmaceutical's total assets of CN¥4.96 Billion consist of 53.5% current assets and 46.5% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 13.1% |
| Accounts Receivable | CN¥472.12 Million | 10.5% |
| Inventory | CN¥187.85 Million | 4.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥168.80 Million | 3.7% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2006–2024)
This chart illustrates how Shanghai Kaibao Pharmaceutical's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Shanghai Kaibao Pharmaceutical market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shanghai Kaibao Pharmaceutical's current assets represent 53.5% of total assets in 2024, a decrease from 70.3% in 2006.
- Cash Position: Cash and equivalents constituted 13.1% of total assets in 2024, up from 5.3% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 1.0% in 2006.
- Asset Diversification: The largest asset category is accounts receivable at 10.5% of total assets.
Shanghai Kaibao Pharmaceutical Competitors by Total Assets
Key competitors of Shanghai Kaibao Pharmaceutical based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
SIMCERE PHARMAC. GRP LTD
F:S2P
|
Germany | €14.73 Billion |
|
Curaleaf Holdings Inc.
TO:CURA
|
Canada | CA$2.88 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥11.13 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
Shanghai Kaibao Pharmaceutical - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 12.39 | 6.36 | 9.34 |
| Quick Ratio | 11.29 | 5.77 | 8.54 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥2.05 Billion | CN¥1.70 Billion | CN¥1.98 Billion |
Shanghai Kaibao Pharmaceutical - Advanced Valuation Insights
This section examines the relationship between Shanghai Kaibao Pharmaceutical's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.45 |
| Latest Market Cap to Assets Ratio | 0.14 |
| Asset Growth Rate (YoY) | -1.3% |
| Total Assets | CN¥4.52 Billion |
| Market Capitalization | $652.05 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shanghai Kaibao Pharmaceutical's assets below their book value (0.14x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Shanghai Kaibao Pharmaceutical's assets decreased by 1.3% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Shanghai Kaibao Pharmaceutical (2006–2024)
The table below shows the annual total assets of Shanghai Kaibao Pharmaceutical from 2006 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥4.52 Billion ≈ $661.19 Million |
-1.34% |
| 2023-12-31 | CN¥4.58 Billion ≈ $670.15 Million |
+7.52% |
| 2022-12-31 | CN¥4.26 Billion ≈ $623.27 Million |
+26.92% |
| 2021-12-31 | CN¥3.36 Billion ≈ $491.06 Million |
+16.63% |
| 2020-12-31 | CN¥2.88 Billion ≈ $421.04 Million |
+1.22% |
| 2019-12-31 | CN¥2.84 Billion ≈ $415.95 Million |
+3.46% |
| 2018-12-31 | CN¥2.75 Billion ≈ $402.03 Million |
+2.53% |
| 2017-12-31 | CN¥2.68 Billion ≈ $392.13 Million |
+6.01% |
| 2016-12-31 | CN¥2.53 Billion ≈ $369.91 Million |
+4.17% |
| 2015-12-31 | CN¥2.43 Billion ≈ $355.10 Million |
+14.61% |
| 2014-12-31 | CN¥2.12 Billion ≈ $309.84 Million |
+19.57% |
| 2013-12-31 | CN¥1.77 Billion ≈ $259.13 Million |
+13.43% |
| 2012-12-31 | CN¥1.56 Billion ≈ $228.44 Million |
+7.48% |
| 2011-12-31 | CN¥1.45 Billion ≈ $212.53 Million |
+5.98% |
| 2010-12-31 | CN¥1.37 Billion ≈ $200.53 Million |
+1.86% |
| 2009-12-31 | CN¥1.35 Billion ≈ $196.87 Million |
+485.27% |
| 2008-12-31 | CN¥229.88 Million ≈ $33.64 Million |
+42.24% |
| 2007-12-31 | CN¥161.61 Million ≈ $23.65 Million |
+48.22% |
| 2006-12-31 | CN¥109.03 Million ≈ $15.96 Million |
-- |
About Shanghai Kaibao Pharmaceutical
Shanghai Kaibao Pharmaceutical CO.,Ltd engages in the research, development, production, and sale of modern traditional Chinese medicines primarily in China. The company offers heat-clearing and detoxifying products, such as Tanreqing Injection for wind-heat in the lungs with phlegm-heat obstructing the lungs, early-stage pneumonia, acute bronchitis, acute exacerbations of chronic bronchitis, and… Read more